John Alam serves as the Chief Executive Officer at CervoMed, co-founding the company (formerly known as EIP Pharma) in 2014. John is an industry leader in translational medicine with over 30 years of experience creating value to help build companies through clinical development success.
Until May 2014, he was therapeutic area head for diseases of aging at Sanofi, where he led all discovery and development activities directed at Alzheimer’s disease, as well as a number of other age-related diseases including sarcopenia/frailty, osteoarthritis, chronic pain and many others. From 1997 to 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and Executive Vice President, Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. Prior to Vertex, Alam led clinical development of Avonex (interferon beta-1a) for multiple sclerosis at Biogen from 1991 to 1997.
John is a member of the board of directors of the Alliance for Aging Research (AAR), a Washington, D.C. based non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. He received a MD from Northwestern University School of Medicine and a BS in Chemical Engineering from the Massachusetts Institute of Technology. In addition, he completed an internal medicine residency at Brigham and Women’s Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.
Robert Cobuzzi serves as the Chief Operating Officer at CervoMed, joining the company in August 2023. Robert has over 25 years of cross-functional leadership experience in the pharmaceutical and biotechnology industries across the areas of corporate development, research & development, and operations.
Previously, Robert served as President, Chief Executive Officer and Board Member of Diffusion Pharmaceuticals from 2020 until 2023. From 2005 until 2018, he held a variety of senior roles in corporate development, R&D and operations at Endo International Plc, including most recently as President, Endo Ventures Limited in Dublin, Ireland. Prior to Endo, he was with Adolor Corporation from 2001 until 2005. Robert began his career in 1995 at AstraMerck in clinical operations before joining Centocor (a subsidiary of Johnson & Johnson) in Worldwide Regulatory Affairs from 1999 to 2001.
Robert also currently serves as a Venture Partner for Sunstone Life Science Ventures and also is Chairman of Sunstone’s Business Development Board. He was previously a member of the U.S. Department of Commerce’s Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health/Science Products and Services, and served as a board member for two development-stage medical device companies. Robert holds an AB in Biochemistry and Art History from Colby College and a PhD in Molecular and Cellular Biochemistry from Loyola University Chicago. He was a post-doctoral fellow in the Department of Experimental Therapeutics at the Roswell Park Cancer Institute in Buffalo, N.Y.
William (Bill) Elder serves as General Counsel and Corporate Secretary at CervoMed, joining the company in August 2023. He is an attorney with nearly a decade of experience advising public and private companies in a variety of corporate, securities, governance, regulatory, and general commercial matters.
Prior to joining CervoMed, Bill served as Diffusion Pharmaceutical’s General Counsel from September 2020 to August 2023 and as its Principal Financial Officer from June 2023 to August 2023, after starting as a consultant for Diffusion in July 2020. Previously, Bill spent eight years as an associate at the law firm of Dechert LLP, counseling clients in a broad range of transactions and other matters, including serving as outside counsel to Diffusion in connection with the Company’s reverse merger in 2016 and several subsequent financings.
Bill received a JD from the University of Pennsylvania School in Law, an MSF from Villanova University, and a BA in Economics from Tufts University.
Kelly Blackburn serves as CervoMed's Senior Vice President of Clinical Development, joining the company (formerly known as EIP Pharma) in May 2018. She has more than 30 years of experience in clinical development operations.
Most recently, Kelly served as Vice President, Clinical Affairs at aTyr Pharma and as Vice President, Clinical Development Operations at Vertex. Of note, she held the senior global clinical operational responsibility for three major novel therapeutics: Kalydeco® for the treatment of cystic fibrosis, Incivek® for hepatitis C, and Velcade® for multiple myeloma.
Kelly is Chair of the board of directors of the Hildebrand Family Self-Help Center, Cambridge MA; and long-standing volunteer case reviewer and emergency foster care mother for the Department of Children and Families in Massachusetts. She has an MHA degree from Quinnipiac University and a BS degree in Biochemistry from the University of New Hampshire.
Dr. De Rosch is an experienced executive pharma/biotech leader (30+ years) mostly with organizations transitioning from early- to late-stage development and to commercialization. He joined CervoMed Inc. in November 2024 as Senior Vice President, Regulatory and Government Affairs, and Program Management and became Executive Vice President in May 2025. Prior to joining CervoMed, He consulted on drug development and global regulatory strategies since May 2023. Previously Dr. De Rosch was Chief Operating Officer at Aura Biosciences from March 2021 to May 2023 overseeing Regulatory Affairs, CMC / Technical Operations, Program & Portfolio Management, Medical Device Innovation, and Information Technology (IT). While at Aura, he contributed to Aura becoming a public company and growing from about 20 employees to about 65 employees to support Phase 3 readiness. Prior to joining Aura, Dr. De Rosch was Chief Regulatory Officer at Epizyme, Inc. where he assisted Epizyme in receiving Accelerated Approval in the US for its first drug, TAZVERIK®, in 2 oncology indications. Prior to Epizyme, he was Senior Vice President of Regulatory, Quality, and Medical Writing at Nightstar Therapeutics, Inc., a gene therapy company specializing in treatment of inherited retinal disease that was acquired by Biogen in 2019. Prior organizations include Akebia Therapeutics, Voisin Consulting Life Sciences, Inspiration Biopharmaceuticals, Vertex Pharmaceuticals, Berlex Laboratories, Diatide, and Mallinckrodt.
He was designated as a Fellow of the Regulatory Affairs Professional Society (FRAPS) in 2017.
Are you a patient, caregiver, clinician or professional and want to learn more about CervoMed’s approach? Please contact us.
Contact UsStrengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON ,
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to
BOSTON , May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced
